title: Effect of infliximab against cisplatin-induced nephrotoxicity.
abstract: OBJECTIVE
  To investigate whether infliximab (Ib), an inhibitor of tumor necrosis factor alpha (TNF-α), prevents cisplatin (Cis)-induced nephrotoxicity.
  
  
  METHODS
  The study was performed in the Department of Internal Medicine, Recep Tayyip Erdogan University, Rize, Turkey, between November 2012 and May 2013. Thirty male Wistar albino rats were divided into 3 groups, a control group, a Cis group, and a Cis+Ib group. The animals of the Cis group were injected with a single dose (7 mg/kg) of Cis intraperitoneally. The animals of the Cis+Ib group were injected with a single dose (7 mg/kg) of Ib 72 hours prior to Cis injection.
  
  
  RESULTS
  The TNF-α, interleukin-1 beta (IL-1b), nitric oxide (NO) and adenosine deaminase (ADA) levels of the Cis group were higher than both the control group TNF-α (p<0.001), IL-1α (p<0.001), NO (p<0.001) and ADA (p<0.001), and the Cis+Ib group TNF-α (p<0.001), IL-1b (p<0.001), NO (p<0.001), and ADA (p=0.003). Histopathological examination revealed extensive damage in the Cis group, while the damage in the Cis+Ib group was lower. While the carbonic anhydrase II (CA-II) level of the Cis group was lower than both groups, it was similar in the Cis+Ib and the control groups.
  
  
  CONCLUSIONS
  Infliximab acts against Cis-induced nephrotoxicity by a strong inhibition of TNF-α. Additionally, the combination of these 2 drugs does not obviously change the level of CA-II.
authors.affiliation: Department of Internal Medicine, School of Medicine, Recep Tayyip Erdogan University, Rize 53100, Turkey. Tel. +90 (464) 2130491 Ext. 1859. Fax. +90 (464) 2170364. E-mail. erkancure@yahoo.com.
authors.forename: Erkan
authors.initials: E
authors.lastname: Cure
authors.forename: Aynur
authors.initials: A
authors.lastname: Kirbas
authors.forename: Levent
authors.initials: L
authors.lastname: Tumkaya
authors.forename: Medine C
authors.initials: MC
authors.lastname: Cure
authors.forename: Osman Z
authors.initials: OZ
authors.lastname: Sahin
authors.forename: Yildiray
authors.initials: Y
authors.lastname: Kalkan
authors.forename: Suleyman
authors.initials: S
authors.lastname: Yuce
authors.forename: Durdu
authors.initials: D
authors.lastname: Altuner
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D000069285:Infliximab; D007668:Kidney / Q000187:drug effects*; D008297:Male; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000069285:Infliximab; D002945:Cisplatin